Gene Expression Analysis in gla-Mutant Zebrafish Reveals Enhanced Ca2+ Signaling Similar to Fabry Disease
Elsaid, Hassan Osman Alhassan; Tjeldnes, Håkon; Rivedal, Mariell Lossius; Serre, Camille Julia; Eikrem, Øystein Solberg; Svarstad, Einar; Tøndel, Camilla; Marti, Hans Peter; Furriol, Jessica; Babickova, Janka
Journal article, Peer reviewed
Published version

Åpne
Permanent lenke
https://hdl.handle.net/11250/3040118Utgivelsesdato
2022Metadata
Vis full innførselSamlinger
- Department of Clinical Medicine [2213]
- Registrations from Cristin [11365]
Originalversjon
International Journal of Molecular Sciences. 2022, 24 (1), 358. https://doi.org/10.3390/ijms24010358Sammendrag
Fabry disease (FD) is an X-linked inborn metabolic disorder due to partial or complete lysosomal α-galactosidase A deficiency. FD is characterized by progressive renal insufficiency and cardio- and cerebrovascular involvement. Restricted access on Gb3-independent tissue injury experimental models has limited the understanding of FD pathophysiology and delayed the development of new therapies. Accumulating glycosphingolipids, mainly Gb3 and lysoGb3, are Fabry specific markers used in clinical follow up. However, recent studies suggest there is a need for additional markers to monitor FD clinical course or response to treatment. We used a gla-knockout zebrafish (ZF) to investigate alternative biomarkers in Gb3-free-conditions. RNA sequencing was used to identify transcriptomic signatures in kidney tissues discriminating gla-mutant (M) from wild type (WT) ZF. Gene Ontology (GO) and KEGG pathways analysis showed upregulation of immune system activation and downregulation of oxidative phosphorylation pathways in kidneys from M ZF. In addition, upregulation of the Ca2+ signaling pathway was also detectable in M ZF kidneys. Importantly, disruption of mitochondrial and lysosome-related pathways observed in M ZF was validated by immunohistochemistry. Thus, this ZF model expands the pathophysiological understanding of FD, the Gb3-independent effects of gla mutations could be used to explore new therapeutic targets for FD.